Literature DB >> 2891905

Penicillin-resistant Borrelia encephalitis responding to cefotaxime.

G S Pal, J T Baker, D J Wright.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2891905     DOI： 10.1016/s0140-6736(88)91021-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Persistence of Borrelia burgdorferi and histopathological alterations in experimentally infected animals. A comparison with histopathological findings in human Lyme disease.

Authors:  V Preac Mursic; E Patsouris; B Wilske; S Reinhardt; B Gross; P Mehraein
Journal:  Infection       Date:  1990 Nov-Dec       Impact factor: 3.553

Review 2.  Lyme disease in paediatrics.

Authors:  B Cryan; D J Wright
Journal:  Arch Dis Child       Date:  1991-11       Impact factor: 3.791

Review 3.  Lyme disease: a review.

Authors:  D Nathwani; N Hamlet; E Walker
Journal:  Br J Gen Pract       Date:  1990-02       Impact factor: 5.386

4.  Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis.

Authors:  V Preac-Mursic; K Weber; H W Pfister; B Wilske; B Gross; A Baumann; J Prokop
Journal:  Infection       Date:  1989 Nov-Dec       Impact factor: 3.553

Review 5.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

6.  Cefotaxime versus penicillin in the late stage of Lyme disease--prospective, randomized therapeutic study.

Authors:  D Hassler; L Zöller; M Haude; H D Hufnagel; F Heinrich; H G Sonntag
Journal:  Infection       Date:  1990 Jan-Feb       Impact factor: 3.553

7.  Formation and cultivation of Borrelia burgdorferi spheroplast-L-form variants.

Authors:  V P Mursic; G Wanner; S Reinhardt; B Wilske; U Busch; W Marget
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

8.  Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis.

Authors:  V Preac Mursic; W Marget; U Busch; D Pleterski Rigler; S Hagl
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

Review 9.  Current recommendations for the treatment of Lyme disease.

Authors:  L H Sigal
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

10.  High-dose intravenous penicillin G does not prevent further progression in early neurological manifestation of Lyme borreliosis.

Authors:  J Kohler; H Schneider; A Vogt
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.